Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 20/20 | 0.81 |
| ▸ | CSNK2A2 | P19784 | 5/20 | 0.65 |
| ▸ | CSNK2B | P67870 | 5/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10168543 | 0.92 | CSNK2A1 (0.69) | CSNK2A1CSNK2A2CSNK2B | |
| SCHEMBL4972094 | 0.91 | CSNK2A1 (0.83) | CSNK2A1CSNK2A2CSNK2B | |
| SCHEMBL4973303 | 0.91 | CSNK2A1 (0.84) | CSNK2A1CSNK2A2CSNK2B | |
| SCHEMBL4975054 | 0.90 | CSNK2A1 (1.00) | CSNK2A1CSNK2A2CSNK2B | |
| SCHEMBL4972876 | 0.89 | CSNK2A1 (0.83) | CSNK2A1CSNK2A2CSNK2B | |
| SCHEMBL16838030 | 0.89 | CSNK2A1 (0.82) | CSNK2A1CSNK2A2CSNK2B | |
| SCHEMBL4973383 | 0.88 | CSNK2A1 (0.85) | CSNK2A1CSNK2A2CSNK2B | |
| SCHEMBL13655588 | 0.87 | CSNK2A1 (0.80) | CSNK2A1CSNK2A2CSNK2B | |
| SCHEMBL12255907 | 0.86 | CSNK2A1 (0.83) | CSNK2A1CSNK2A2CSNK2B | |
| SCHEMBL4971925 | 0.85 | CSNK2A1 (0.81) | CSNK2A1CSNK2A2CSNK2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8168651-B2 | Protein kinase modulators | CYLENE PHARMACEUTICALS, INC. (US) | 2012-05-01 | — | — | US | disclosed |
| US-20110263581-A1 | FUSED TRICYCLIC COMPOUNDS AS SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| US-7956064-B2 | Fused tricyclic compounds as serine-threonine protein kinase and PARP modulators | CYLENE PHARMACEUTICALS, INC. (US) | 2011-06-07 | — | — | US | disclosed |
| US-20090105233-A1 | SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS | SENHWA BIOSCIENCES, INC. (TW) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263581-A1 | FUSED TRICYCLIC COMPOUNDS AS SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS | PARP1, PARP11, TNKS | CSNK2A1 66/4885CSNK2A2 90/4885CSNK2B 105/4885 |
| US-20090105233-A1 | SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS | PACSIN2, TNKS, PARP1 | CSNK2A1 24/4885CSNK2A2 37/4885CSNK2B 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.